SCHEMBL2641377

SCHEMBL2641377

O=[C]COc1cc(Cl)c(Cl)cc1Cl

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1I2 O75469 1/20 0.60
ADRA2A P08913 1/20 0.60
ADORA3 P0DMS8 1/20 0.60
ADRA2B P18089 1/20 0.60
ADRA2C P18825 1/20 0.60
TACR2 P21452 1/20 0.60
DRD1 P21728 1/20 0.60
SLC6A2 P23975 1/20 0.60
HTR2A P28223 1/20 0.60
HTR2C P28335 1/20 0.60
ADORA1 P30542 1/20 0.60
SLC6A4 P31645 1/20 0.60
OPRM1 P35372 1/20 0.60
DRD3 P35462 1/20 0.60
OPRK1 P41145 1/20 0.60
HTR6 P50406 1/20 0.60
SLC6A3 Q01959 1/20 0.60
KCNH2 Q12809 1/20 0.60
GALE Q14376 1/20 0.60
LMNA P02545 3/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3737958 0.78 NR1I2 (0.60) NR1I2ADRA2AADORA3ADRA2BADRA2C
SCHEMBL2641277 0.78 TDP1 (0.56) TSHRTDP1MAPTNPSR1SMN1; SMN2
SCHEMBL22558160 0.78 NR1I2 (0.46) NR1I2ADRA2AADORA3ADRA2BADRA2C
SCHEMBL11331289 0.78 ALDH1A1 (0.45) LMNATSHRTDP1ALDH1A1RAB9A
Haloprogin SCHEMBL30128207 0.75 NR1I2 (1.00) NR1I2ADRA2AADORA3ADRA2BADRA2C
Haloprogin SCHEMBL3649 0.75 NR1I2 (1.00) NR1I2ADRA2AADORA3ADRA2BADRA2C
SCHEMBL14529596 0.75 NR1I2 (0.67) NR1I2ADRA2AADORA3ADRA2BADRA2C
Haloprogin SCHEMBL8165340 0.75 NR1I2 (1.00) NR1I2ADRA2AADORA3ADRA2BADRA2C
SCHEMBL96506 0.72 MEN1 (0.47) LMNATSHRTDP1L3MBTL1MAPT
SCHEMBL978758 0.72 NR1I2 (0.52) NR1I2ADRA2AADORA3ADRA2BADRA2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105777640-B Pyrazole cyclohexanediol ether compound and application thereof 沈阳中化农药化工研发有限公司 2020-01-07 CN claimed
CN-105777640-A Pyrazole cyclohexanediol ether compounds and applications thereof 沈阳中化农药化工研发有限公司 2016-07-20 CN claimed
EP-0675895-B1 ETOPOSIDE DERIVATIVES, PROCESS FOR THEIR PREPARATION, THEIR USE AS A DRUG AND IN THE PREPARATION OF A DRUG FOR TREATING CANCER PF MEDICAMENT (FR) 1997-07-23 EP claimed
US-5643885-A Etoposide derivatives, process for preparing them, their use as a medicinal product and their use for the preparation of a medicinal product intended for anti-cancer treatment PIERRE FABRE MEDICAMENT (FR) 1997-07-01 US claimed
JP-H08504795-A 1996-05-21 JP claimed
EP-0675895-A1 ETOPOSIDE DERIVATIVES, PROCESS FOR THEIR PREPARATION, THEIR USE AS A DRUG AND IN THE PREPARATION OF A DRUG FOR TREATING CANCER. FABRE PIERRE COSMETIQUE (FR) 1995-10-11 EP claimed
WO-1994014829-A1 ETOPOSIDE DERIVATIVES, PROCESS FOR THEIR PREPARATION, THEIR USE AS A DRUG AND IN THE PREPARATION OF A DRUG FOR TREATING CANCER PIERRE FABRE MEDICAMENT (FR) 1994-07-07 WO claimed
CN-114206831-A Conjugates of auxin analogs 以色列国家农业部、农村发展农业研究组织·沃尔卡尼中心 2022-03-18 CN disclosed
EP-3956294-A1 CONJUGATES OF AUXIN ANALOGS The State of Israel, Ministry of Agriculture and Rural Development, Agricultural Research Organization (ARO) (Volcani Center) (IL) 2022-02-23 EP disclosed
US-20220030866-A1 CONJUGATES OF AUXIN ANALOGS THE STATE OF ISRAEL, MINISTRY OF AGRICULTURE & RURAL DEVELOPMENT, AGRICULTURAL RESEARCH ORGANIZATION (IL) 2022-02-03 US disclosed
WO-2020212993-A1 CONJUGATES OF AUXIN ANALOGS THE STATE OF ISRAEL, MINISTRY OF AGRICULTURE & RURAL DEVELOPMENT, AGRICULTURAL RESEARCH ORGANIZATION (ARO) (VOLCANI CENTER) (IL) 2020-10-22 WO disclosed
CN-105777640-B Pyrazole cyclohexanediol ether compound and application thereof 沈阳中化农药化工研发有限公司 2020-01-07 CN disclosed
CN-105777640-A Pyrazole cyclohexanediol ether compounds and applications thereof 沈阳中化农药化工研发有限公司 2016-07-20 CN disclosed
US-6750344-B1 MONOCYCLIC AMINE SCAFFOLD BEARING AT LEAST TWO SITES OF DIVERSITY, CYCLIZED TO FORM BICYCLIC AMINE SCAFFOLDS; 7-AMINO-PYRROLO(1,2-A)PYRAZIN-4-ONE COMPOUNDS ISIS PHARMACEUTICALS, INC. 2004-06-15 US disclosed
US-6559303-B1 Bridgehead atoms are bonded to one or more bridges that interconnect one or more ring systems thereby forming a large cyclic structure. Located in each bridge are two or more nitrogenous moieties that are derivatized with chemical ISIS PHARMACEUTICALS, INC. 2003-05-06 US disclosed
EP-0675895-B1 ETOPOSIDE DERIVATIVES, PROCESS FOR THEIR PREPARATION, THEIR USE AS A DRUG AND IN THE PREPARATION OF A DRUG FOR TREATING CANCER PF MEDICAMENT (FR) 1997-07-23 EP disclosed
US-5643885-A Etoposide derivatives, process for preparing them, their use as a medicinal product and their use for the preparation of a medicinal product intended for anti-cancer treatment PIERRE FABRE MEDICAMENT (FR) 1997-07-01 US disclosed
EP-0675895-A1 ETOPOSIDE DERIVATIVES, PROCESS FOR THEIR PREPARATION, THEIR USE AS A DRUG AND IN THE PREPARATION OF A DRUG FOR TREATING CANCER. FABRE PIERRE COSMETIQUE (FR) 1995-10-11 EP disclosed
WO-1994014829-A1 ETOPOSIDE DERIVATIVES, PROCESS FOR THEIR PREPARATION, THEIR USE AS A DRUG AND IN THE PREPARATION OF A DRUG FOR TREATING CANCER PIERRE FABRE MEDICAMENT (FR) 1994-07-07 WO disclosed
US-4349488-A Process for producing esters of 3,5-dibromo-4-hydroxybenzonitrile GREAT LAKES CHEMICAL CORPORATION (US) 1982-09-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220030866-A1 CONJUGATES OF AUXIN ANALOGS CROCC, CCNY, AGXT NR1I2 1744/4885ADRA2A 1436/4885ADORA3 62/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.